Norstella
Citeline Podcasts
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Určitě navštivte web podcastu a podpořte jeho tvůrce: www.citeline.com
Kde poslouchat?
Podcasty v aplikaci Replaio Radio Už brzyPodcasty míří do aplikace už brzy. Nainstaluj si ji teď a jako první uvidíš úplně nový pohled na podcasty
Epizody
Due Diligence Podcast: Why Are Reverse Mergers Increasing Despite Rising IPO Activity 19.11.2026 46:43
Biotech execs Matt Davidson and Sheila Gujrathi and attorney Mike Blankenship join Scrip’s Joseph Haas to discuss the uptick of reverse mergers in 2026 and the factors driving that trend.
Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once 17.11.2026 45:13
Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organizatio...
China Biopharma English-Language Podcast: Does China Reimburse Its Most Innovative Drugs? 16.11.2026 6:40
In this episode of the China biopharma English-language podcast, Xu Hu in Shanghai talks about the insurance coverage of the most innovative drugs approved in China between 2020 and 2026 under the country’s mainstay medical insurance program. Who developed those medicines? Which therapeutic area is the most dominant? The story featured in this episode: Does China Reimburse Its Most Innovative Drug...
Drug Fix: US FDA’s CNPV Program Ends, Commissioner Nominee’s Day Of Reckoning Arrives 13.11.2026 33:27
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Prevision Policy Founding Member Mike McCaughan consider the lessons learned from the US Food and Drug Administration’s Commissioner’s National Priority Voucher (CNPV) program as it officially sunsets (1:13) and its legacy (16:31). They also discuss FDA commissioner nominee Heidi Overton’s pros...
Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power 13.11.2026 49:16
Conventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David Wild talks with Harris Kaplan (managing partner, Litmys), Sal Grouso (senior market access executive), and Roxanne Schwans (founder and CEO, OmniHealth Rx Advisors). Kaplan and Grouso recently published an article in In Vivo...
Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience 10.11.2026 20:28
In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.
Over The Counter: Earning The Pharmacist’s Recommendation, With Thorrun Govind 09.11.2026 26:44
When a customer asks a pharmacist what to take, brand awareness only gets a product so far. A recommendation has to be earned, says pharmacist, healthcare lawyer and broadcaster Thorrun Govind. Govind, a former chair of the Royal Pharmaceutical Society’s English Pharmacy Board, joins HBW Insight’s Over the Counter podcast to talk about how manufacturers can win that trust. We discuss how pharmacis...
【3分で解説 #世界のファーマ】第32回 民主党逆転の米国中間選挙 製薬業界への影響は?(Japanese-language podcast) 09.11.2026 3:38
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら Democratic Wins In Congress Will Fuel MFN, FDA Oversight, May Advance Bipartisan Legislation https://insights.citeline.com/pink-sheet/legislation/elections/democratic-wins-in-congress...
Drug Fix: How Will US FDA Navigate Midterm Blue Wave’s Aftermath? 06.11.2026 34:03
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential changes that the midterm election rout by Democrats could create for the US Food and Drug Administration in the short-term as agency officials await confirmation of a new commissioner and a new funding bill (1:02), as well as longer-term when the user fee package (14:12) a...
Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine? 06.11.2026 40:25
"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moderna’s personalized melanoma vaccine cut the risk of recurrence or death by 42% in a Phase 3 trial. So,...
【3分で解説 #世界のファーマ】第32回 民主党逆転の米国中間選挙 製薬業界への影響は?(Japanese-language podcast) 06.11.2026 4:05
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら Democratic Wins In Congress Will Fuel MFN, FDA Oversight, May Advance Bipartisan Legislation https://insights.citeline.com/pink-sheet/legislation/elections/democratic-wins-in-congres...
Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs 02.11.2026 23:06
For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experiences, as well as evolving stakeholder expectations, early in development plays an important role in shaping a more informed evidence strategy. In this podcast,...
Drug Fix: Could Other Products Use Peptide Order For Access, Industry Opposes CRL Release 30.10.2026 34:12
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs consider the impact of the Health and Human Services Department’s temporary order allowing compounding of unapproved peptides on the drug industry (1:58), including whether stakeholder could use the precedent to gain access to other products (4:05). They also analy...
Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans 27.10.2026 30:17
In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market analysis across Europe and US, as well as growing therapeutics area trends within biotech.
Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview 22.10.2026 29:05
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.
Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck? 20.10.2026 29:01
Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb (MedTech Insight) speaks with Dr. Soeren Mattke, research professor of economics at USC, director of the Brain Health Observatory, and member of the scientific advisory board of ALZpath, about how FDA-cleared blood tests are...
Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt 19.10.2026 27:04
In the latest episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.
Drug Fix: What Drove US FDA Generics Chief To Step Down And New Rare Disease Framework 16.10.2026 28:02
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the reasons Iilun Murphy, director of the US Food and Drug Administration’s Office of Generic Drugs, decided to step down (:53) and whether the move should concern senior agency officials (2:51). They also consider the FDA’s plan to create a fit-for-purpose rare disease approval framewor...
Scrip Chinese-Language Podcast - Oct. 14, 2026 15.10.2026 17:38
本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括:中国带来的竞争威胁;第三季度并购活动降温;新型肺炎球菌疫苗竞争者;西班牙生物技术公司的战略;以及盐野义制药20亿美元的收购案。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-...
Digital Health Roundup: BD’s $19Bn Tariff Deal, Longevity, GLP-1 Tools Chasing Proof 15.10.2026 18:23
In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-use device; George Underwood, Reset Health’s GLP-1 adherence data; and Marion Webb, Hillary Lin’s evidence-based longevity care;
Scrip's Five Must-Know Things - Oct. 13, 2026 13.10.2026 16:21
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 9, 2026. This time—China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s...
Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown 13.10.2026 26:44
Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it takes to commercialize a topical dermatology drug in an increasingly scrutinized promotional environment. Commercial strategies, ad campaigns, dermatology
Drug Fix: US FDA’s Peptide Drama, More Transparency, Ibogaine Clinical Trial Plans 09.10.2026 41:03
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Senior Reporter Maaisha Osman discuss the drama unfolding at the US Food and Drug Administration related to a Health and Human Services Department plan to temporarily allow some compounding of unapproved peptides (:52). They also consider the impact of the FDA’s intent to acknowledge indivi...
Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike 06.10.2026 24:03
In the third episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė is joined by Sandoz’s head of IP Julia Pike to analyze the European intellectual property system, how it compares to the US, and the financial decisions behind litigation for off-patent companies. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.
Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’ 06.10.2026 33:16
In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela Tanaerts, CMO and CSO at Medable, to discuss promising data from an AI Clinical Monitoring Agent.
Podobné podcasty
Replaio není vydavatelem podcastů; názvy pořadů, obálky a audio patří jejich autorům a šíří se přes veřejné RSS kanály